Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer 
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review

Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer 
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review

Lung cancer is the most common malignant disease and the leading cause of cancer death in China. Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung cancers, and the probability of NSCLC gene mutations is high, with a wide variety of types. With the development of next-generation se...

Full description

Bibliographic Details
Main Authors: Chunmei CHEN, Yang YU, Meijuan HUANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
afatinib
crispld2-nrg1 fusion mutation
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.19

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.19

Similar Items